 If a patient has had a coronary CTA within the past two 2 months, they will not undergo the procedure at enrollment. If the patient has not had a coronary CTA within the past two 2 months, they will undergo a coronary CTA with contrast. Patients will be randomly assigned to receive either the study treatment 135 mg of TriLipix plus 40 mg of Atorvastatin or the comparison treatment a placebo or two pills that contains no active treatment. They will have a 50 chance of receiving the study treatment and a 50 chance of receiving the comparison treatment. This is a double-blind study, which means the patient, the research staff, and the physician will not know which treatment the patient is receiving. However, in case of an emergency, this information is immediately available to the physician. 